CCL2 and liver cancer: These results combined with the above data verified that overexpressed β-arrestin2 may down-regulate the activation of β2-AR/Akt signaling and the secretion of CCL2 in HSCs, and thus inhibiting the proliferation and migration of liver cancer cells.